Physician profile
Deandra Dagen
NPI 1700191426
$1,868.92
in general payments reported to CMS, 2019-2025
23 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $484 · 2022: $376 · 2023: $442 · 2024: $333 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.09 |
| Education | $193.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $276.61 | 2021-2025 | |
| Astellas Pharma US INC | $276.59 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $169.03 | 2021-2022 | |
| Hologic Sales and Service, LLC | $152.19 | 2021-2025 | Aptima, Myosure Tissue Removal Device, Acessa Provu System |
| Biogen, INC. | $125.89 | 2024-2025 | Zurzuvae |
| Organon LLC | $122.87 | 2021-2024 | Nexplanon |
| Abbvie INC. | $117.77 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $115.45 | 2021-2023 | |
| Coopersurgical, INC. | $97.54 | 2021-2024 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $61.04 | 2021 | |
| Medtronic, INC. | $53.09 | 2022-2024 | Venaseal |
| Therapeuticsmd, INC. | $48.44 | 2022 | |
| Dexcom, INC. | $38.77 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $35.09 | 2021-2024 | Gardasil 9, Gardasil |
| Boston Scientific Corporation | $31.16 | 2023 | Solyx Sis System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $27.67 | 2021 | |
| Axonics, INC. | $20.89 | 2021 | |
| Ethicon US, LLC | $20.76 | 2024 | Enseal X1 |
| Mycovia Pharmaceuticals, INC. | $20.72 | 2023 | Vivjoa |
| Millicent US INC | $14.54 | 2025 | Intrarosa, Femring |
| Agile Therapeutics, INC. | $14.53 | 2023 | Twirla |
| Virtus Pharmaceuticals LLC | $14.15 | 2021 | |
| Myovant Sciences INC. | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deandra Dagen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.